Takafumi Yanagisawa

Urologist@Jikei University School of Medicine

[Shingo Hatakeyama @ShingoHatakeya1]

Top10％閲覧論文に選ばれたようです。
Full text views:3744
Citations: 14...2025年に出版され、8ヶ月 (0.666年)で14 citesなので、この論文の瞬間最大IFは21点！（笑）

Comparison of ABI, ENZ, APA for mHSPC: A multicenter study - Yanagisawa T- 2025 - The Prostate https://t.co/IywIPiFY2A

[Jikei Urology @jikei_urology]

🎉Our JHA group study on abiraterone, enzalutamide & apalutamide in mHSPC: Top 10 most-cited in The Prostate 2024!

https://t.co/73kBtwqyC3

[Jikei Urology @jikei_urology]

📈Our systematic review and meta-analysis on prognostic factors of PSMA-targeted radioligand therapy in mCRPC is now featured on @UroToday's "Beyond the Abstract".

We discussed the key predictors for treatment outcomes. Check it out here:

https://t.co/JSxfgaJqB1
#mCRPC #PSMA

[Jikei Urology @jikei_urology]

🎆London calling : 13 abstracts from the Team Jikei Urology have been accepted by the EAU 🇬🇧🇬🇧🇬🇧
See you in London!

@gehi87
@F_Urabe
@Macchan1055
@ene1the1r0nk1d

[Jikei Urology @jikei_urology]

34th Malaysian Urological Conference:
MUC2025
Dr. Yanagisawa was invited and spoke at the Plenary session about En-bloc TUR-BT
and Dr. Enei gave a presentation about PSMA-RLT for the best poster competition
@gehi87
@Enenny_SS
@MyUrologyAssoc

[Shingo Hatakeyama @ShingoHatakeya1]

PSMAddition キタ〜

第III相PSMAddition試験は、mHSPC治療に放射性リガンド療法を導入

1,144例のPSMA陽性患者
ADT＋ARPIに¹⁷⁷Lu-PSMA-617を追加投与することで、無再発生存期間（rPFS）が有意に改善（HR 0.72、p = 0.002）

85%がLu-PSMA全6サイクルを完了

[Shingo Hatakeyama @ShingoHatakeya1]

大変重要な議論でした
全員に6回必要？
PSMA陽性部位が少ないと効果落ちてAE増える
途中でPSMA陽性部位を確認する必要性を示唆

[Japan Society for Endoscopic Surgery (JSES) @jses_eng]

JSES IllustCon 17
📌Robot-Assisted Radical Nephrectomy and IVC Thrombectomy
📝The distal IVC was stapled and transected. IVC was cranially clamped and the Pringle maneuver was also performed. Then the tumor was directly identified and resected with IVC. These procedures are illustrated in a single figure.
🖊Dr.Cazz
#JSESイラストコンテスト　#JSES_illustration_contest

[Shingo Hatakeyama @ShingoHatakeya1]

慈恵の柳澤先生らによる、mUCのメタ解析
EVPが効果1ランク上の模様だかAEも2位とのこと

https://t.co/9KCpkkbBCl

[Jeremy Teoh @jteoh_hk]

The #UroSoMe dinner! Fun group of urologists from all around the world joining hands to do meaningful work together! #EAU25

[Shingo Hatakeyama @ShingoHatakeya1]

これが噂の、泌尿器科ドラマ！

39才女性の筋層浸潤膀胱癌はレアすぎて…？80歳のMIBCや結石性腎盂腎炎ならザラですが…

女医相手に下ネタが止まらない精巣腫瘍の患者もまあ不在です

[Eur Urol Focus @EurUrolFocus]

Radical cystectomy (RC) and trimodality therapy (TMT) yield comparable outcomes in muscle-invasive bladder cancer (MIBC)?
✨ 74.4% complete response with TMT.
🔄 23.1% recurrence rate in TMT-treated patients.
⚠️ 11.4% grade ≥3 toxicity for TMT.

Does this change your practice?

[European Urology Oncology @EurUrolOncol]

Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis by Akihiro Matsukawa et al

https://t.co/xcIgyxDRtZ

#UroSoMe #MedTwitter #EUO #PCa #ProstateCancer

[Jeremy Teoh @jteoh_hk]

@gehi87 from @jikei_urology talking about SR, MA & NMA! Dr Takafumi Yanagisawa is such a hardworking and talented researcher. Thank you for sharing with us your valuable experiences! #UroSoMe

[Dean Elterman @DrDeanElterman]

@Ric_Campi discussing how @eau_yuo brings together today/tomorrows leaders to create teams for academic impact @Uroweb #ARISTA symposium @jteoh_hk @MRoupret @DocGauhar #Inspiring

[Juan Gómez Rivas @JGomezRivas]

Recent advances in managing biochemical recurrence (BCR) after local treatment for prostate cancer (PCa) 🎯

📊 We analyzed 19 studies (9117 patients) to compare different salvage therapies post-radical prostatectomy (RP) or radiation therapy (RT). Results show that combining RT with hormone therapy offers significant improvements in metastatic-free survival (MFS)! 🌟

🔍 Key findings:
- RT + hormone therapy = ⬆️ MFS
- Best RT-based strategy: Prostate bed RT + elective nodal RT + ADT
- Top hormone-based strategy: Enzalutamide + ADT for MFS & OS

🧬 For high-risk BCR or post-RT recurrence, consider adding ARSI (androgen receptor signaling inhibitors) to ADT.

🚑 These combinations represent the next step in PCa care, ensuring better outcomes for patients!

https://t.co/cIr7zrZLlV

#ProstateCancer #CancerResearch #urooncology #BCR #AndrogenTherapy #RadicalProstatectomy #RadiationTherapy #CancerTreatment

@ZilliThomas @joniau

[Jikei Urology @jikei_urology]

1st Int'l Urologic Cancer Symposium: Renowned urologists from 3 countries gave informative talks. Great dinner followed, joined by Dr. Teoh & Dr. Leung.

[Jikei Urology @jikei_urology]

Join us for the 1st Int'l Urologic Cancer Symposium in Tokyo!
8/28, 18:30-20:30 Jikei Uni.
Featuring ＠dr_rajwa, @BenjaminPradere & ＠FQuhal. Open to all, including non-institution members!

[BJU International @BJUIjournal]

First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy
@gehi87 @E_Laukhtina @K_Tatsushi @DrShariat @schmidingerRCC

https://t.co/I6u98dMTLg

[Jeremy Teoh @jteoh_hk]

The EB-StaR study was published at European Urology today! ✅ It is a randomised study comparing en bloc resection of bladder tumour (ERBT) and conventional transurethral resection of bladder tumour (TURBT) in patients with bladder tumour(s) <= 3 cm in size. 🏥 #UroSoMe (1/n)